GP方案与TP方案治疗初治晚期非小细胞肺癌疗效的临床观察

目的 探讨GP方案和TP方案对初治晚期非小细胞肺癌的疗效和毒性.方法 72例晚期非小细胞肺癌（ⅢB期50例,Ⅳ期22例）随机分成GP组和TP组,入组的每例患者接受至少2个周期以上的GP或TP同样方案的化疗,比较两组不同化疗方案的近期疗效和毒副反应,以及1、2年的生存率.结果 GP和TP两组近期疗效的有效率分别为44.4％、47.2％,中位生存期：GP组8.7个月、TP组8.5个月,1年生存率：GP组16.6％、TP组19.4％,2年生存率：GP组8.3％、TP组11.1％.两组数据统计学均无显著性差异.毒副反应：GP组以血小板降低为主,TP组以白细胞降低为主,均在可耐受的范围内.结论 GP和TP两种化疗方案对晚期非小细胞肺癌具有很好的临床疗效,化疗毒副反应虽有所不同,但均可耐受.因此GP和TP两种化疗方案均可作为晚期非小细胞肺癌的一线治疗方案.

Clinical observation on original chemotherapy for advanced non-small cell lung cancer between GP and TP

Objective TO evaluate the efficacy and toxicity of the GP and TP regimens on advanced non- small cell lung cancer. Methods 72 patients with advanced non-small cell lung cancer were divided into the GP and the TP group randomly, in all case, 50 patients were in stage IIIB, 22 patients in stage IV , all the patients had accepted intravenous chemotherapy and preponderated over 2cycles. A clinical observation on short term effectiveness adverse effects and the 1,2-year-survival state were carried out in two groups. Results The short term effective rate for advanced non-small cell lung cancer in GP group and TP group was 44.4% and 47.2% , respectively. The median survival time was 8.7 months and 8.5 months, respectively. 1-year survival rate was 16.6% and 19.4%, respectively. 2-year survival rate was 8.3% and 11.1% . The short term effectiveness and the 1,2-year-survival state in two groups had no statistically significant difference （ P 〉 0. 05 ）. In the adverse effects of treatment, the major cytotoxicity was thrombocytopenia in GP group and leukopenia in TP group but they were tolerable. Conclusions Both GP and TP regimens on advanced non-small cell lung cancer show more effectiveness. The side effects of the two regimens are different but all adverse reactions are tolerable. They could become the original chemotherapy in advanced non-small cell lung cancer.